Share on StockTwits

Equities researchers at Canaccord Genuity began coverage on shares of SAGE Therapeutics (NASDAQ:SAGE) in a research report issued on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $40.00 price target on the stock. Canaccord Genuity’s price target would indicate a potential upside of 33.51% from the stock’s previous close.

A number of other analysts have also recently weighed in on SAGE. Analysts at JPMorgan Chase & Co. initiated coverage on shares of SAGE Therapeutics in a research note on Tuesday. They set an “overweight” rating and a $42.00 price target on the stock. Separately, analysts at Goldman Sachs initiated coverage on shares of SAGE Therapeutics in a research note on Tuesday. They set a “neutral” rating on the stock. Finally, analysts at Leerink Swann initiated coverage on shares of SAGE Therapeutics in a research note on Tuesday. They set an “outperform” rating on the stock.

Shares of SAGE Therapeutics (NASDAQ:SAGE) opened at 33.40 on Tuesday. SAGE Therapeutics has a 1-year low of $24.25 and a 1-year high of $34.88. The stock has a 50-day moving average of $28.74 and a 200-day moving average of $28.74. The company’s market cap is $833.7 million.

SAGE Therapeutics, Inc is a biopharmaceutical company. The Company is focused on development and commercialization of therapies for the treatment of life-threatening, rare central nervous system (NASDAQ:SAGE) disorders.

The Fly On The Wall

Receive News & Ratings for SAGE Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.